Molecular pathways associated with transcriptional alterations in hyperparathyroidism

Lee,Fang; Lee,Jie‑Jen; Jan,Woan‑Ching; Wu,Chih‑Jen; Chen,Han‑Hsiang; Cheng,Shih‑Ping

doi:10.3892/ol.2016.4623

Molecular pathways associated with transcriptional alterations in hyperparathyroidism

Authors:
- Fang Lee
- Jie‑Jen Lee
- Woan‑Ching Jan
- Chih‑Jen Wu
- Han‑Hsiang Chen
- Shih‑Ping Cheng
View Affiliations

Affiliations: Department of Surgery, MacKay Memorial Hospital and MacKay Medical College, Taipei 10449, Taiwan, R.O.C., Department of Nursing, MacKay Junior College of Medicine, Nursing and Management, Tapei 11260, Taiwan, R.O.C., Department of Pharmacology and Graduate Institute of Medical Sciences, Taipei Medical University, Taipei 11031, Taiwan, R.O.C.
Published online on: May 25, 2016 https://doi.org/10.3892/ol.2016.4623
Pages: 621-626

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hyperparathyroidism is characterized by the oversecretion of parathyroid hormone biochemically and increased cell proliferation histologically. Primary and secondary hyperparathyroidism exhibit distinct pathophysiology but share certain common microscopic features. The present study performed the first genome‑wide expression analysis directly comparing the expression profile of primary and secondary hyperparathyroidism. Microarray gene expression analyses were performed in parathyroid tissues from 2 primary hyperparathyroidism patients and 3 secondary hyperparathyroidism patients. Unsupervised hierarchical clustering analysis identified two natural subgroups containing different types of hyperparathyroidism. Combined with additional data extracted from a publicly available database, a meta‑signature was constructed to represent an intersection of two sets of differential expression profile. Multiple pathways were identified that are aberrantly regulated in hyperparathyroidism. In primary hyperparathyroidism, dysregulated pathways included cell adhesion molecules, peroxisome proliferator‑activated receptor signaling pathway, and neuroactive ligand‑receptor interaction. Pathways implicated in secondary hyperparathyroidism included tryptophan metabolism, tight junctions, renin‑angiotensin system, steroid hormone biosynthesis, and O‑glycan biosynthesis. The present study demonstrates that different pathophysiology is associated with differential gene profiling in hyperparathyroidism. Several pathways are involved in parathyroid dysregulation and may be future targets for therapeutic intervention.

View Figures

View References

1	Fraser WD: Hyperparathyroidism. Lancet. 374:145–158. 2009. View Article : Google Scholar : PubMed/NCBI
2	Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C and Potts JT Jr: Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop. J Clin Endocrinol Metab. 99:3561–3569. 2014. View Article : Google Scholar : PubMed/NCBI
3	Cheng SP, Lee JJ, Liu TP, Yang PS, Liu SC, Hsu YC and Liu CL: Quality of life after surgery or surveillance for asymptomatic primary hyperparathyroidism: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 94:e9312015. View Article : Google Scholar : PubMed/NCBI
4	Cheng SP, Lee JJ, Liu TP, Yang TL, Chen HH, Wu CJ and Liu CL: Parathyroidectomy improves symptomatology and quality of life in patients with secondary hyperparathyroidism. Surgery. 155:320–328. 2014. View Article : Google Scholar : PubMed/NCBI
5	Elliott DD, Monroe DP and Perrier ND: Parathyroid histopathology: Is it of any value today? J Am Coll Surg. 203:758–765. 2006. View Article : Google Scholar : PubMed/NCBI
6	Drueke T, Martin D and Rodriguez M: Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant. 22:1828–1839. 2007. View Article : Google Scholar : PubMed/NCBI
7	Bingham EL, Cheng SP, Woods Ignatoski KM and Doherty GM: Differentiation of human embryonic stem cells to a parathyroid-like phenotype. Stem Cells Dev. 18:1071–1080. 2009. View Article : Google Scholar : PubMed/NCBI
8	Thomopoulou GE, Tseleni-Balafouta S, Lazaris AC, Koutselini H, Kavantzas N and Davaris PS: Immunohistochemical detection of cell cycle regulators, Fhit protein and apoptotic cells in parathyroid lesions. Eur J Endocrinol. 148:81–87. 2003. View Article : Google Scholar : PubMed/NCBI
9	Shan L, Nakamura Y, Nakamura M, Yokoi T and Kakudo K: Genetic alterations in primary and secondary hyperparathyroidism. Pathol Int. 48:569–574. 1998. View Article : Google Scholar : PubMed/NCBI
10	Westin G, Björklund P and Akerström G: Molecular genetics of parathyroid disease. World J Surg. 33:2224–2233. 2009. View Article : Google Scholar : PubMed/NCBI
11	Cheng SP, Lee JJ, Liu TP, Chen HH, Wu CJ and Liu CL: Aluminum overload hampers symptom improvement following parathyroidectomy for secondary hyperparathyroidism. World J Surg. 38:2838–2844. 2014. View Article : Google Scholar : PubMed/NCBI
12	Cheng SP, Yin PH, Chang YC, Lee CH, Huang SY and Chi CW: Differential roles of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep. 23:1721–1727. 2010.PubMed/NCBI
13	Au AY, McDonald K, Gill A, Sywak M, Diamond T, Conigrave AD and Clifton-Bligh RJ: PTH mutation with primary hyperparathyroidism and undetectable intact PTH. N Engl J Med. 359:1184–1186. 2008. View Article : Google Scholar : PubMed/NCBI
14	Benjamini Y and Yekutieli D: False discovery rate-adjusted multiple confidence intervals for selected parameters. J Am Stat Assoc. 100:71–81. 2005. View Article : Google Scholar
15	Cheng SP, Doherty GM, Chang YC and Liu CL: Leptin: The link between overweight and primary hyperparathyroidism? Med Hypotheses. 76:94–96. 2011. View Article : Google Scholar : PubMed/NCBI
16	Dwight T, Nelson AE, Theodosopoulos G, Richardson AL, Learoyd DL, Philips J, Delbridge L, Zedenius J, Teh BT, Larsson C, et al: Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism. Am J Pathol. 161:1299–1306. 2002. View Article : Google Scholar : PubMed/NCBI
17	Newey PJ, Nesbit MA, Rimmer AJ, Attar M, Head RT, Christie PT, Gorvin CM, Stechman M, Gregory L, Mihai R, et al: Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. J Clin Endocrinol Metab. 97:E1995–E2005. 2012. View Article : Google Scholar : PubMed/NCBI
18	Costa-Guda J and Arnold A: Genetic and epigenetic changes in sporadic endocrine tumors: Parathyroid tumors. Mol Cell Endocrinol. 386:46–54. 2014. View Article : Google Scholar : PubMed/NCBI
19	Lee JY, Kim SY, Mo EY, Kim ES, Han JH, Maeng LS, Lee AH, Eun JW, Nam SW and Moon SD: Upregulation of FGFR1 expression is associated with parathyroid carcinogenesis in HPT-JT syndrome due to an HRPT2 splicing mutation. Int J Oncol. 45:641–650. 2014.PubMed/NCBI
20	Segiet OA, Deska M, Michalski M, Gawrychowski J and Wojnicz R: Molecular profiling in primary hyperparathyroidism. Head Neck. 37:299–307. 2015. View Article : Google Scholar : PubMed/NCBI
21	Shan L, Nakamura M, Nakamura Y, Inoue D, Morimoto S, Yokoi T and Kakudo K: Comparative analysis of clonality and pathology in primary and secondary hyperparathyroidism. Virchows Arch. 430:247–251. 1997. View Article : Google Scholar : PubMed/NCBI
22	Shi Y, Hogue J, Dixit D, Koh J and Olson JA Jr: Functional and genetic studies of isolated cells from parathyroid tumors reveal the complex pathogenesis of parathyroid neoplasia. Proc Natl Acad Sci USA. 111:3092–3097. 2014. View Article : Google Scholar : PubMed/NCBI
23	Tominaga Y, Kohara S, Namii Y, Nagasaka T, Haba T, Uchida K, Numano M, Tanaka Y and Takagi H: Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg. 20:744–750; discussion 750–752. 1996. View Article : Google Scholar : PubMed/NCBI
24	Tharmalingam S, Daulat AM, Antflick JE, Ahmed SM, Nemeth EF, Angers S, Conigrave AD and Hampson DR: Calcium-sensing receptor modulates cell adhesion and migration via integrins. J Biol Chem. 286:40922–40933. 2011. View Article : Google Scholar : PubMed/NCBI
25	Tomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, Verheyen N, Gaksch M, Grübler M, Fahrleitner-Pammer A, Mrak P, et al: Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 63:20–31. 2014. View Article : Google Scholar : PubMed/NCBI
26	Porsti I, Fan M, Kööbi P, Jolma P, Kalliovalkama J, Vehmas TI, Helin H, Holthofer H, Mervaala E, Nyman T and Tikkanen I: High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure. Kidney Int. 66:2155–2166. 2004. View Article : Google Scholar : PubMed/NCBI
27	Brown JM, Williams JS, Luther JM, Garg R, Garza AE, Pojoga LH, Ruan DT, Williams GH, Adler GK and Vaidya A: Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Hypertension. 63:273–280. 2014. View Article : Google Scholar : PubMed/NCBI
28	Pons F, Torregrosa JV and Fuster D: Biological factors influencing parathyroid localization. Nucl Med Commun. 24:121–124. 2003. View Article : Google Scholar : PubMed/NCBI
29	Huang TS, Lee JJ, Lin YC and Cheng SP: Fluorodeoxyglucose-avid parathyroid adenoma mimicking thyroid incidentaloma. ANZ J Surg. 80:763–764. 2010. View Article : Google Scholar : PubMed/NCBI
30	Hindié E, Zanotti-Fregonara P, Tabarin A, Rubello D, Morelec I, Wagner T, Henry JF and Taïeb D: The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. J Nucl Med. 56:737–744. 2015. View Article : Google Scholar : PubMed/NCBI